Life sciences company Naveris has expanded its Series A financing to $33.4m, bringing its total investment to $51m, for advancing the commercialisation of its NavDx blood test.

Led by Gurnet Point Capital, the financing round also included the impact and venture capital arm of the American Cancer Society, as well as BrightEdge and TechU Ventures. 

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

NavDx has been designed to detect cancers that are caused by the human papillomavirus (HPV) in the early stages.

It is claimed to be the first and only clinically validated circulating tumour-tissue-modified HPV (TTMV) DNA blood test.

The blood test uses proprietary technology to quantify fragments of circulating TTMV HPV DNA, which is a unique HPV-driven cancer biomarker shed by cancer cells into the blood.

It reliably discovers the HPV+ head and neck cancer presence across the care continuum.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The NavDx test reports are easy-to-interpret and help physicians make clinical decisions for the treatment of cancer in the early stages, which could lead to improved outcomes.

Naveris founder and CEO Piyush Gupta said: “We founded Naveris on the belief that advances in molecular diagnostics will play a vital role in improving cancer outcomes.

“This new investment underscores NavDx’s commercial success and potential, and our experienced team’s ability to transform this vision into a reality for patients and oncologists.”

Additionally, the company will use the financing round proceeds to generate the required clinical data for expanding into other cancer types and indications.

More than 25 medical institutions have collaborated with Naveris and used its technology to conduct clinical studies.

Furthermore, Naveris has teamed up with biotechnology companies that are developing immunotherapies for the treatment of HPV-related cancers.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact